Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: A randomised double-blinded trial by 源��궓�삤 et al.
Eur J Anaesthesiol 2016; 33:275–282
From the Department of
Cardiovascular Surgery
Correspondence to You
Seoul 120-752, South
Tel: +82 2 2228 2420
0265-0215 Copyright 
This is an open-access
download and share theAn
(C
ng
Kor
; fa
2
art
wL ARTICLEORIGINAEffects of dexmedetomidine on oxygenation and lung
mechanics in patients with moderate chronic obstructive
pulmonary disease undergoing lung cancer surgery
A randomised double-blinded trial
Su Hyun Lee, Namo Kim, Chang Yeong Lee, Min Gi Ban and Young Jun OhBACKGROUND Chronic obstructive pulmonary disease
(COPD) is a risk factor that increases the incidence of
postoperative cardiopulmonary morbidity and mortality after
lung resection. Dexmedetomidine, a selective a2-adrenore-
ceptor agonist, has been reported previously to attenuate
intrapulmonary shunt during one-lung ventilation (OLV) and
to alleviate bronchoconstriction.
OBJECTIVE The objective is to determine whether dexme-
detomidine improves oxygenation and lung mechanics in
patients with moderate COPD during lung cancer surgery.
DESIGN A randomised, double-blinded, placebo-controlled
study.
SETTING Single university hospital.
PARTICIPANTS Fifty patients scheduled for video-assisted
thoracoscopic surgery who had moderate COPD. Patients
were randomly allocated to a control group or a Dex group
(n¼25 each).
INTERVENTIONS In the Dex group, dexmedetomidine was
given as an initial loading dose of 1.0mg kg1 over 10min
followed by a maintenance dose of 0.5mg kg1 h1 during
OLV while the control group was administered a comparable
volume of 0.9% saline. Data were measured at 30minaesthesiology and Pain Medicine (SHL, NK, MGB, YJO), Ana
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MAIN OUTCOME MEASURES The primary outcome was
the effect of dexmedetomidine on oxygenation. The second-
ary outcome was the effect of dexmedetomidine adminis-
tration on postoperative pulmonary complications.
RESULTS Patients in the Dex group had a significantly
higher PaO2/FIO2 ratio (27.95.8 vs. 22.58.4 and
28.65.9 vs. 21.09.9 kPa, P<0.05), significantly lower
dead space ventilation (19.28.5 vs. 24.18.1 and
19.66.7 vs. 25.37.8%, P<0.05) and higher dynamic
compliance at DEX-30 and DEX-60 (P¼0.0001 and
P¼0.0184) compared with the control group. In the Dex
group, the PaO2/FIO2 ratio in the postoperative period was
significantly higher (P¼0.022) and the incidence of ICU
admission was lower than in the control group.
CONCLUSION Dexmedetomidine administration may pro-
vide clinically relevant benefits by improving oxygenation and
lungmechanics in patients with moderate COPD undergoing
lung cancer surgery.
TRIAL REGISTRATION ClinicalTrial.gov identifier: NCT
02185430.
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Chronic obstructive pulmonary disease (COPD) is a risk
factor that increases the incidence of postoperative car-
diopulmonary morbidity and mortality after lung resec-
tion.1–3 COPD is a physiological condition in whichpatients display airflow limitations because of narrowing
of peripheral bronchioles. Decreased elastic recoil and
structural changes of the small airways and alveoli cause
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276 Lee et al.chronic alveolar hypoxia results in medial hypertrophy of
the pulmonary arteriole and structural changes, such as
muscularisation.5 In COPD patients, hypoxaemia is
caused by intrapulmonary right-to-left shunt and the
uneven distribution of alveolar ventilation and pulmon-
ary perfusion. The high ventilation/perfusion area inter-
feres with effective CO2 elimination, possibly resulting in
hypercapnia.6,7 One-lung ventilation (OLV) aggravates
the intrapulmonary shunt and dead space, whereas grav-
itational effects and hypoxic pulmonary vasoconstriction
(HPV) act as protective mechanisms.8,9 However,
decreased pulmonary artery compliance and increased
pulmonary artery stiffness are reported in early COPD
without pulmonary hypertension,10,11 and the HPV
responses have been reported to be less efficient in
patients with COPD.12 Furthermore, the treatment strat-
egies for hypoxaemia induced by OLV, such as positive
end-expiratory pressure (PEEP) and alveolar recruit-
ment, cannot be applied to COPD patients because of
concern about high intrinsic PEEP development.
In addition to b-adrenoreceptors in the smooth muscle of
the bronchus, a1 and a2-adrenoreceptors are found in the
bronchial mucosa and ganglia. Bronchodilators that are
currently used target the b-adrenoreceptors of the bron-
chial wall, as bronchodilator effects of a-adrenoreceptors
have not yet been proved. Dexmedetomidine, which is a
selective a2-adrenoreceptor agonist, was reported to
effectively inhibit histamine-induced bronchoconstric-
tion in an animal study13 and to decrease the intrapul-
monary shunt during OLV in healthy patients.14 In
addition, dexmedetomidine is known to decrease pul-
monary arterial pressure directly,15 and it does not
increase pulmonary arterial pressure in patients with
pre-existing pulmonary hypertension.16–18 However,
whether or not dexmedetomidine can exert beneficial
effects on oxygenation and lung mechanics in COPD
during OLV remains unclear.
The primary object of this randomised trial was to assess
the effects of dexmedetomidine on oxygenation and lung
mechanics during OLV in patients with moderate
COPD. The secondary end point was to assess the effects
of dexmedetomidine administration on postoperative
pulmonary complications.
Methods
This study received approval from the institutional
review board of Severance Hospital, Yonsei University
Health System, Seoul, South Korea (Ref. 4-2014-0306) in
July 2014 and was registered at Clinical Trials.gov (NCT
02185430). All participants provided written informed
consent before participation. Patients expected to
undergo video-assisted thoracoscopic surgery for lung
lobectomy were included. The inclusion criteria were
as follows: age more than 40 years, American Society of
Anaesthesiologists’ physical status 2 or 3, a diagnosis of
COPD of moderate grading, and a forced expiratoryEur J Anaesthesiol 2016; 33:275–282volume in 1 s (FEV1) of at least 50% and less than
80% of predicted with the presence of a post-broncho-
dilator FEV1/forced vital capacity ratio less than 0.70 in a
preoperative pulmonary function test.19 The exclusion
criteria were heart failure (New York Heart Association
class > II), a history of arrhythmia or treatment with
antiarrhythmic drugs, bradycardia [heart rate (HR) <45
beats min1] or atrioventricular block, severe functional
liver or kidney disease, obesity (body mass index
>30 kg m2), restrictive lung disease and/or decreased
lung diffusion capacity for carbon monoxide (DLCO
<70%).
Enrolled patients were randomly allocated to a control
(0.9% saline) group or a Dex (dexmedetomidine) group
using a randomised sequence generated by a computer,
and the randomisation process was centralised. A con-
cealed envelope for random allocation was sent to the
anaesthesia nurses who prepared the dexmedetomidine
or saline. Therefore, the anaesthesiologist administered
the drug in a blind manner. The participating anaesthe-
tists, nurses, surgeons and patients were blinded to the
treatment allocation.
Patients were monitored with standard monitoring
devices upon arrival at the operating room. Anaesthesia
was induced with propofol, remifentanil and rocu-
ronium. Tracheal intubation was performed with a left-
sided double-lumen tube (Broncho-Cath, Mallinckrodt,
Dublin, Ireland), and the position of the double-lumen
tube was confirmed with a fibre-optic bronchoscope
before OLV. After induction of anaesthesia, a 20-gauge
radial artery catheter was inserted, and a 7-FG central
venous catheter (Arrow, Teleflex Incorporated, Wayne,
PA, USA) was inserted through the right internal jugular
vein. The inserted length of the central venous catheter
was calculated using a height-based formula so that the
tip would lie near the right atrium.20 Anaesthesia was
maintained with 1.0 to 3.0% sevoflurane, remifentanil
and rocuronium. The lungs were initially ventilated in
autoflow pressure-controlled ventilation mode (Primus i
ventilator, Dra¨ger TM Medical, Lu¨beck, Germany) with a
tidal volume of 8 ml kg1 and an inspiratory : expiratory
(I : E) ratio of 1 : 2.5. During OLV, the lungs were venti-
lated in autoflow pressure-controlled ventilation mode
with a tidal volume of 6 ml kg1 and PEEP of 3 cmH20 for
protective ventilation. In all patients, PEEP of 3 cmH20
was applied but discontinued if the peak airway pressure
exceeded 30 mmHg. The fraction of inspired oxygen
(FIO2) was initially set at 0.6 and in cases of desaturation
to SaO2 less than 95%, FIO2 was increased by 0.2 up to
1.0. The respiratory rate was adjusted to maintain an end-
tidal CO2 tension (EtCO2) of 5 to 6 kPa. During the
study, the depth of anaesthesia was adjusted to maintain
a bispectral index of 40 to 60. If the bispectral index
decreased below 40, the concentration of sevoflurane was
reduced. The concentration of sevoflurane in exhaled gas
was monitored. In the Dex group, dexmedetomidine
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Fig. 1
Assessed for eligibility (n = 70)
Excluded (n = 7)
♦ Not meeting inclusion criteria(n = 4)
♦ Declined to participate(n = 3) 
Analysed (n = 25)
♦ Excluded from analysis (n = 0) 
Lost to follow-up: incomplete data (n = 2)
Discontinued intervention: change
of surgical plan (n = 7)
Allocated to dexmedetomidine group
♦ Received allocated intervention (n = 34)
Lost to follow-up: incomplete data (n = 1)
Discontinued intervention: change of
surgical plan (n = 3)
Allocated to control group
♦ Received allocated intervention (n = 29)
Analysed  (n = 25)
♦ Excluded from analysis (n = 0)
Allocation
Analysis
Follow-up
Randomised (n = 63) 
Enrolment
Study flow diagram.(Precedex, Hospira, Lake Forest, IL, USA) was started
once the patient was haemodynamically stable 30 min
after the initiation of OLV; a bolus of 1.0mg kg1 was
administered over 10 min followed by a continuous infu-
sion at 0.5mg kg1 h1 for 1 h. A comparable volume of
0.9% saline was administered to patients in the control
group.
The object of this trial was to evaluate the effects of
dexmedetomidine on patients with moderate COPD
undergoing lung cancer surgery. The primary outcome
was lung oxygenation expressed as the PaO2/FIO2 ratio.
The secondary outcome was to assess the effects of
dexmedetomidine administration on postoperative pul-
monary complications. Arterial blood gases were analysed
(GEM Premier 4000, Instrumentation Laboratory, Lex-
ington, MA, USA) at three time points: 30 min after the
initiation of OLV (OLV), 30 min after dexmedetomidine
administration during OLV (DEX-30) and 60 min after
dexmedetomidine administration during OLV (DEX-
60). The respiratory variables included PaO2/FIO2 ratio,
PaCO2, EtCO2, dead space ventilation, peak airway pres-
sure, tidal volume and dynamic compliance. The phys-
iological dead space ventilation (Vd/Vt) was calculated
as follows according to the Hardman & Aitkenhead
equation:21 Vd/Vt¼ 1.14 (PaCO2–EtCO2)/PaCO2 –0.005. Dynamic compliance and plateau airway pressure
were obtained from the Primus i ventilator. Dynamic
compliance was automatically calculated as tidal volume/
(plateau airway pressure – PEEP). The haemodynamic
measurements included HR and systolic and diastolic
blood pressures. Vasoactive drugs, such as ephedrine,
were administered if the mean arterial pressure decreased
by more than 20% from baseline arterial pressure, and
atropine was administered if HR decreased to less than
45 beats min1. If the SaO2 measured by pulse oximetry
decreased to less than 90% during OLV, two-lung venti-
lation was reinstuted, and the event was recorded. The
double-lumen tube was removed after the end of surgery.
To evaluate the secondary end point of pulmonary com-
plications, respiratory rate and PaO2 /FIO2 ratio were
recorded 20 min after arrival at the post-anaesthetic care
unit (PACU), and incidences of postoperative atelectasis,
pneumonia and acute lung injury (ALI) were assessed for
72 h. In the PACU, if the patient showed signs of dyspnoea
with a concurrent PaO2/FIO2 ratio less than 40 kPa, the
patient required ICU admission. ALI was defined as the
following: PaO2/FIO2 ratio less than 40 kPa (300 mmHg);
diffuse pulmonary infiltration at 72 h; exclusion of hydro-
static pulmonary oedema because of other primary causes,
including cardiac insufficiency or fluid overload.22Eur J Anaesthesiol 2016; 33:275–282
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Table 1 Patients’ characteristics and operative data
Dex group
(nU25)
Control group
(nU25)
Age (years) 68.46.4 69.48.7
Sex (M/F) 12/13 11/14
Height (cm) 162.96.9 162.38.4
Weight (kg) 60.88.9 61.38.9
BMI (kgm2) 22.32.7 22.72.1
ASA physical status, 2/3 11/14 12/3
Hypertension 10 11
Cardiovascular medication
RAAS inhibitor 8 8
Calcium channel blocker 1 2
b-adrenergic antagonists 0 1
Furosemide 2 2
Smoking
Ex-smoker/current smoker 11/12 14/10
Smoking index, pack-years 36.727.1 35.828.9
Non-smoker 2 1
Medication
Inhaled corticosteroid 42.7% 39.5%
Oral corticosteroid 18.6% 14.3%
Inhaled bronchodilator 21.3% 17.9%
Oral bronchodilator 33.6% 34.2%
Muscarinic antagonists 3.7% 3.2%
Preoperative SpO2, % 93.81.2 94.11.3
Preoperative spirometry
FEV1, % predicted 60.85.2 61.44.1
FVC, % predicted 82.78.6 83.17.2
FEV1/FVC, % 55.93.2 56.15.7
FEF25–75%, l s
1 26.418.9 27.119.3
FEF50%, l s
1 18.911.3 19.312.7
DLco, % predicted 93.68.2 92.37.6
Intraoperative data
Anaesthesia time (min) 193.624.6 189.744.1
Operation time (min) 163.839.4 158.133.2
OLV time (min) 125.637.1 124.741.2
Fluid intake (ml) 791.492.3 813.279.5
Urine output (ml) 274.5132.6 354.6132.7
Estimated blood loss (ml) 122.455.6 125.684.7
Number receiving ephedrine 9M 1
Right/left lobectomy 17/8 16/9
Right upper lobe 8 5
Right middle lobe 2 5
Right lower lobe 7 6
Left upper lobe 4 6
Left lower lobe 4 3
Values are meanSD, number or percentage of patients. ASA, American Society
of Anesthesiologists; DLco, diffusion capacity of lung for carbon monoxide;
FEF25–75%, forced expiratory volume between 25 and 75% of the FVC;
FEF50%, forced expiratory volume 50% of the FVC; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; OLV, one-lung ventilation; RAAS,
renin–angiotensin–aldosterone system; SpO2, oxygen saturation (pulse
oximetry). MP<0.05 vs. control group.Statistical analysis
The primary outcome was lung oxygenation expressed
by PaO2/FIO2 ratio during OLV. A previous study
23
showed that the meanSD value of PaO2/FIO2 ratio
during OLV in patients with COPD was 22.7 7.0 kPa.
A PaO2 /FIO2 ratio difference of 6.7 kPa between the
two groups is considered to be significant. We calcula-
ted that a sample size of 23 patients was required in
each group at a power of 90%, with a two-sided
significance level of 0.05 by an independent t-test. To
account for a 10% dropout rate, we included 25 patients
in each group. Results are expressed as meanSD or
median (IQR). Adjusted odds ratios (OR) and 95%
confidence intervals (CIs) were calculated for indepen-
dent variables. Intergroup comparisons at each time
point were determined by unpaired t-tests, Mann–
Whitney U-tests and x2 or Fisher exact tests. Variables
with repeated measures were analysed using a linear
mixed model with patient indicator as a random effect
and group, time, and group-by-time as fixed effects. The
statistical analyses were performed with SPSS 20.0
software (IBM Corporation, Armonk, NY, USA), and
P values less than 0.05 were considered statistically
significant.
Results
Seventy patients were determined to be eligible for this
study, but four patients were excluded at initial screening
and three patients declined to participate. Of the 63
patients, 13 were excluded from the study because of
incomplete data and/or changes of surgical plan. Data
from 25 patients in each group were analysed (Fig. 1).
There were no differences between groups regarding
baseline characteristics. The frequency of ephedrine
administration was significantly greater in the Dex group
(Table 1).
Intraoperative data are shown in Table 2. In comparison
with the control group, there were significant haemody-
namic changes in patients in the Dex group. HR at DEX-
30 and DEX-60 was significantly lower compared with
values at the same times in the control group (P< 0.001).
In addition, mean blood pressure was significantly lower
in the Dex group than in the control group (P< 0.05).
The end-tidal concentrations of sevoflurane were similar
in the two groups.
Results of blood gas analysis and lung mechanics are
shown in Fig. 2 and Table 2. The PaO2/FIO2 ratio was
significantly higher at DEX-30 and DEX-60 in the Dex
group compared with the control group (27.9 5.8 vs.
22.5 8.4 and 28.6 5.9 vs. 21.0 9.9 kPa, P¼ 0.026 and
0.009). In the Dex group, dead space ventilation at DEX-
30 and DEX-60 was significantly lower compared with
the control group (19.2 8.5 vs. 24.1 8.1 and 19.6 6.7
vs. 25.3 7.8%, P¼ 0.046 and 0.013). Dynamic compli-
ance was higher at DEX-30 and DEX-60 in the Dex
group compared with the control group. Plateau airwayEur J Anaesthesiol 2016; 33:275–282pressure was significantly lower in the Dex group at
DEX-30 and DEX-60.
Postoperative data are shown in Table 3. In the PACU,
PaO2 /FIO2 ratio was significantly higher in the Dex
group than in the control group. Seven patients in the
control group had episodes in which SaO2 was less than
95% and PaO2/FIO2 ratio was less than 40 kPa while
breathing room air, eventually resulting in respiratory
care in the ICU, with one patient ultimately diagnosed
with ALI. In comparison, only one patient in the Dex
group required respiratory care in the ICU after lung
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Table 2 Haemodynamic and respiratory changes in 50 patients with moderate chronic obstructive pulmonary disease during one-lung
ventilation
Dex group (nU25) Control group (nU25) P GroupT Time
Heart rate (beatsmin1) <0.001
OLV 76.67.6 81.111.6
DEX-30 63.29.8M,MM 76.48.3
DEX-60 58.86.0M,MM 77.08.5
MBP (mmHg) 0.014
OLV 84.813.6 81.112.1
DEX-30 70.710.9M,MM 82.26.3
DEX-60 68.99.5M,MM 76.55.1
Et SEVO (vol%) 0.078
OLV 2.00.5 2.00.4
DEX-30 1.80.2 2.00.4
DEX-60 1.90.2 2.20.4
BIS 0.022
OLV 56.98.9 54.66.6
DEX-30 41.55.5M,MM 53.68.6
DEX-60 40.27.3M,MM 52.55.8
PaCO2 (kPa) 0.027
OLV 6.20.3 6.10.3
DEX-30 5.60.3M,MM 5.90.5
DEX-60 5.70.3M,MM 6.10.6
Ppeak (cmH2O) 0.001
OLV 22.33.9 22.54.9
DEX-30 18.23.2M,MM 23.04.1
DEX-60 18.22.7M,MM 21.74.3
Compliance (ml cmH2O
1) 0.018
OLV 19.54.9 19.25.2
DEX-30 22.53.5M,MM 17.73.4
DEX-60 21.44.2M,MM 18.14.6
Values are meanSD. BIS, bispectral index; Compliance, dynamic compliance; Control, control group; Dex, dexmedetomidine group; DEX-30, 30min after
dexmedetomidine administration during OLV; DEX-60, 60min after dexmedetomidine administration during OLV; Et SEVO, concentration of sevoflurane in exhaled
gas; MBP, mean blood pressure; OLV, 30min after initiation of OLV; PaCO2, arterial carbon dioxide tension; Ppeak, peak airway pressure.
MP<0.05 versus Control group.
MMP<0.05 versus OLV within the same group.
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Table 3 Postoperative outcome of 50 patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery
Dex group (nU25) Control group (nU25) P OR
PaO2/FIO2 ratio at PACU (kPa) 47.57.1M 42.25.9 0.022
Need for ICU stay 1 7 0.049 9.33 (1.05 to 82.78)
Atelectasis 0 4 0.110 10.67 (0.54 to 209.65)
Length of hospital stay (days) 6.5 (5 to 10) 7.1 (6 to 11) 0.102
Focal lung infiltration 1 2 >0.99 2.09 (0.18 to 24.61)
ALI 0 1 >0.99 3.12 (0.12 to 80.39)
Values are meanSD, number of patients, median (IQR) OR (95% CI). ALI, acute lung injury; Dex, dexmedetomidine; OR, odds ratio; PACU, post-anaesthetic care unit.
MP<0.05 vs. control group.
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280 Lee et al.surgery. Patients in the Dex group had fewer incidences
of atelectasis (Dex group 0%, control group 16%), focal
lung infiltration (Dex group 4%, control group 8%). The
duration of hospital stay did not differ between groups.
Discussion
This randomised trial assessed the effects of dexmede-
tomidine on oxygenation and lung mechanics of patients
with moderate COPD undergoing lung cancer surgery.
Dexmedetomidine improved oxygenation by decreasing
dead space ventilation and dynamic compliance in
patients with moderate COPD during the surgery, with
significantly higher postoperative PaO2/FIO2 ratios and
fewer pulmonary complications.
High ventilation/perfusion mismatch, which is caused by
luminal narrowing of pulmonary arterioles and air-trap-
ping hyperinflation, is considered the cause of hypoxae-
mia and hypercapnia in COPD.6 In patients with COPD,
the response to HPV does not activate effectively
because of the remodelled pulmonary vascular structure
and altered pulmonary vascular reactivity.24 Further-
more, even in patients with early COPD without coex-
isting pulmonary hypertension, decreased pulmonary
vascular resistance and increased pulmonary artery stiff-
ness can possibly inhibit the activation of HPV.11 Accord-
ing to the global initiative for [chronic obstructive] lung
disease classification,19 COPD is assessed as moderate
when FEV1 is at least 50%, and 80% or less of predicted,
and severe if FEV1 is more than 30%, and 50% or less of
predicted with a post-bronchodilator FEV1/ forced vital
capacity ratio less than 0.70.
Previous studies of COPD have focused on hyperinfla-
tion and intrinsic PEEP because of air trapping during
OLV in patients with severe COPD.25,26 Our results
revealed that the PaO2/FIO2 ratio in the control group
was comparable with that of previously reported PaO2/
FIO2 ratios in COPD patients during OLV.
23,25,26 How-
ever, there is controversy in the literature regarding the
results of some studies which have claimed significantly
higher PaO2/FIO2 ratios than we found.
27 Furthermore,
there is a continuing dispute over intrinsic PEEP and
oxygenation during OLV in COPD patients. Although
Bardoczky et al.,26 assert that intrinsic PEEP and oxygen-
ation have a negative correlation, other views have been
expressed by, for example, Aschkenasy et al.,27 who
stated that intrinsic PEEP may delay events of hypox-
aemia in severe COPD patients when compared with
healthy patients. Some authors have explained that
intrinsic PEEP caused by the hyperinflation of ventilated
lungs in patients with severe COPD increases the func-
tional residual capacity and improves oxygenation during
OLV.27,28 However, they did not evaluate the statistical
difference.28 In light of this, Michelet et al.23 insisted that
moderate to severe COPD patients had better PaO2/FIO2
ratios than healthy patients during OLV. This hypothesis
was based on the idea that high intrinsic PEEP couldEur J Anaesthesiol 2016; 33:275–282induce more entrapped lung volume in severe COPD. In
our study, intrinsic PEEP rarely occurred during OLV. In
addition, Yokota et al.29 could not confirm the correlations
between intrinsic PEEP and oxygenation, and preopera-
tive forced expiratory volume and oxygenation have not
been shown to correlate during OLV.30 There are larger
numbers of patients with mild to moderate COPD than
severe COPD.31,32 Thus, further studies are required to
explore the physiological consequences of mild to mod-
erate COPD during OLV.
In this study, dexmedetomidine administration
decreased dead space ventilation and improved dynamic
compliance and oxygenation. Dexmedetomidine has
been reported to have a bronchodilator effect in hista-
mine-induced bronchoconstriction when it was adminis-
tered intravenously in an animal study,13 but no clinical
studies have confirmed this effect. Some authors have
found that dexmedetomidine improves oxygenation and
respiratory dynamics during OLV in healthy patients.14,33
They suggested that a sparing effect of the inhalational
agent by dexmedetomidine administration ameliorated
HPV inhibition or increased perfusion in the ventilated
lung by vasodilatation. However, the concentrations of
sevoflurane were similar in both groups in the present
study, and it seems more likely that dexmedetomidine
affects lung mechanics directly in COPD to increase the
threshold of hypoxaemia during OLV, rather than having
an inhalation anaesthetic-sparing effect.
There is limited data about how dexmedetomidine
affects the pulmonary vasculature and perfusion.
Although perioperative dexmedetomidine adminis-
tration is known to increase systemic blood pressure
temporarily, its effect on pulmonary arterial pressure
has rarely been studied. A previous study showed that
dexmedetomidine administration decreased pulmonary
arterial pressure when given through a peripheral vein,
and it did not increase pulmonary arterial pressure
even after direct injection into the pulmonary artery.15
Several studies have reported that dexmedetomidine
does not elevate pulmonary arterial pressure after cardiac
surgery.34,35 Clinically, administration of dexmedetomi-
dine decreases pulmonary arterial pressure effectively in
patients with existing pulmonary hypertension after car-
diac surgery.18 Recently, it was reported that dexmede-
tomidine does not affect the pulmonary vasculature in
patients with existing pulmonary hypertension.36,37
Furthermore, Nathan et al.17 reported that dexmedeto-
midine improved respiratory status during sedation in
patients without pulmonary arterial pressure elevation.
As we did not have direct evidence to verify pulmonary
arterial pressure and pulmonary vascular resistance in this
study, we cannot determine whether dexmedetomidine
improved oxygenation by increasing pulmonary per-
fusion. However, considering the decrease of dead space
ventilation and improvement of PaO2/FIO2 ratio after
dexmedetomidine administration, dexmedetomidine
Effects of dexmedetomidine in moderate chronic obstructive lung disease 281could act as a pulmonary vasodilator which increases
perfusion to the dead space ventilation portion of the
ventilated lung in moderate COPD patients. Therefore,
further study regarding the mechanism of dexmedeto-
midine on the pulmonary vasculature and broncho-
alveolar system is needed.
Regardless of the novel findings of the present study,
there are several limitations to take into account. First,
although high FIO2 can possibly increase the risk of
pulmonary atelectasis, lead to absent ventilation in low
ventilation/perfusion areas of the lung and result in a high
alveolar-arterial O2 tension difference,
38 we allowed for
an increase of FIO2 at an increment of 0.2 up to FIO2 1.0
in response to hypoxaemia. Because our goal was to
prevent hypoxaemia during OLV, we set our focus on
detection of intraoperative hypoxaemia rather than post-
operative hypoxaemia. Second, this study was conducted
on patients with moderate COPD. Consequently, we
cannot assume the same results of dexmedetomidine
administration in patients with severe COPD, which is
characterised by irreversibility of airflow limitation,
hyperdynamic inflation and resultant high intrinsic
PEEP. Third, we could not confirm whether the enrolled
patients had pulmonary hypertension before surgery.
Because pulmonary artery catheters are not inserted
routinely in clinical settings, we could not measure the
pulmonary vascular resistance, or directly measure mixed
venous oxygen tension. Fourth, the primary outcome of
this trial was lung oxygenation expressed by PaO2/FIO2
ratio and respiratory mechanics during OLV. Thus, the
results from this study are underpowered to confirm the
secondary outcome of postoperative pulmonary compli-
cations. Fifth, it is currently recognised that inhaled
anaesthetics have an effect on intrapulmonary shunt
during OLV. To minimise the effects of inhaled anaes-
thetics and focus on the direct effects of dexmedetomi-
dine on lung mechanics, we maintained anaesthesia with
the lowest possible concentration of sevoflurane in both
groups. Nonetheless, we cannot exclude possible effects
of deep anaesthesia by inhaled anaesthetics on lung
mechanics. Finally, this study included a relatively small
number of patients and further studies will be needed to
verify our findings in both moderate and severe COPD
patient groups.
In conclusion, dexmedetomidine provides clinically
relevant benefits in patients with moderate COPD
undergoing lung cancer surgery. Dexmedetomidine
administration during OLV not only improved oxygen-
ation but also reduced dead space ventilation in patients
with moderate COPD. The positive effects of dexme-
detomidine extended to the postoperative period, with
the potential for better outcome after lung surgery.
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